Systematic symptom management in the IMPACT Consortium: rationale and design for 3 effectiveness-implementation trials
- PMID: 37930033
- PMCID: PMC10627528
- DOI: 10.1093/jncics/pkad073
Systematic symptom management in the IMPACT Consortium: rationale and design for 3 effectiveness-implementation trials
Abstract
Cancer and its treatment produce deleterious symptoms across the phases of care. Poorly controlled symptoms negatively affect quality of life and result in increased health-care needs and hospitalization. The Improving the Management of symPtoms during And following Cancer Treatment (IMPACT) Consortium was created to develop 3 large-scale, systematic symptom management systems, deployed through electronic health record platforms, and to test them in pragmatic, randomized, hybrid effectiveness and implementation trials. Here, we describe the IMPACT Consortium's conceptual framework, its organizational components, and plans for evaluation. The study designs and lessons learned are highlighted in the context of disruptions related to the COVID-19 pandemic.
Published by Oxford University Press 2023.
Conflict of interest statement
The authors have nothing to disclose.
Figures
References
-
- Batra A, Yang L, Boyne DJ, et al. Associations between baseline symptom burden as assessed by patient-reported outcomes and overall survival of patients with metastatic cancer. Support Care Cancer. 2021;29(3):1423-1431. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical